An open trial of olanzapine in children and adolescents with Asperger Disorder [2]

Journal of Clinical Psychopharmacology

Volumn 26, Issue 1, 2006, Pages 90-92

  Milin, Robert ^a   Simeon, Jovan G ^a   Batth, Sue ^a   Thatte, Smita ^a   Dare, Glenda J ^a   Walker, Selena ^a  

^a ROYAL OTTAWA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; RISPERIDONE;

ADOLESCENT; ASPERGER SYNDROME; ATTENTION DISTURBANCE; AUTISM; BEHAVIOR DISORDER; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERGLYCEMIA; LETTER; MALE; NAUSEA; PRIORITY JOURNAL; SCHOOL CHILD; SEDATION; SIDE EFFECT; SINUS TACHYCARDIA; SOCIAL INTERACTION; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; ASPERGER SYNDROME; BENZODIAZEPINES; CHILD; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 31544458933     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000196114.93376.86     Document Type: Letter

References (13)

1. Loetspeich LJ, Kwon H, Schumann CM, et al. Investigation of neuroanatomical differences between autism and Asperger Syndrome. Arch Gen Psychiatry. 2004;61:291-298.
2. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314-321.
3. Light M, Dunbar F, Shea SE. The efficacy and safety of Risperidone in the treatment of children with autistic disorder and other pervasive developmental disorders: a randomized, double-blind, placebo-controlled study. Presented at the Collegium Internaionale Neuro-Psychopharmacologicum Congress; 2004; Paris, France.
4. McDougle CJ, Brodkin ES, Naylor ST, et al. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol. 1998;18(1):62-66.
5. Malone RP. Olanzapine versus Haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry. August 2001:1-17.
6. Masi G. Pharmacotherapy of pervasive developmental disorders in children and adolescents. CNS Drugs. 2004;18(14):1031-1052.
7. Achenbach TM, Edelbrock C. Manual of Child Behavior Checklist and Revised Child Behavior Profile. Burlington: University of Vermont; 1983.
8. Edelbrock C, Achenbach TM. The teacher version of the child behavior profile: I boys aged 6-11. Consult Clin Psychol. 1984;52:207-217.
9. Ehlers S, Gillberg C, Wing L. A screening questionnaire for Asperger Syndrome and other high-functioning autism spectrum disorders in school age children. J Autism Dev Disord. 1999;29(2):129-141.
10. National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). Early Clin Drug Eval Unit Intercom. 1975;4:3-6.
11. Bryson SE, Rogers A, Fombonne E. Autism spectrum disorders: early detection, intervention, education, and psychopharmacological management. Can J Psychiatry. 2003;48(8):506-516.
12. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;622(suppl 7):22-31.
13. Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone,olanzapine,and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. 2004;29:133-145.